Search Results
Found 7 results for "switzerland" across articles, medicines, trials, companies and the glossary
Industry
The €8.5 Billion Defense: Dutch Innovative Pharma Fights Back Against Cost-Control Policies
The Dutch Association for Innovative Medicines (VIG) releases a detailed report highlighting the sector\'s €8.5 billion gross added value, warning that cost-containment measures threaten patient access, clinical trials, and Europe\'s biopharma sovereignty.
Regulatory Affairs
GEODIS Expands Pharmaceutical Logistics in Poland: Securing Dual GDP and IATA CEIV Pharma Certifications
GEODIS has renewed its IATA CEIV Pharma accreditation in Warsaw and secured GDP certification for its Stryków Dobra contract logistics facility. This dual compliance milestone bolsters Poland’s status as a critical gateway in Europe’s pharmaceutical supply chain.
Regulatory Affairs
Beyond the Headline: Are Irish Pharma Workers Truly the Highest Paid in Europe?
Recent reports suggest Irish pharma workers are the highest paid in Europe, but a deeper dive reveals a more complex reality. We analyze compensation packages, tax regimes, and cost of living across Europe’s top pharmaceutical hubs.
Pharmaceutical
The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector
An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.
Regulatory Affairs
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.
Industry
Laprophan Accelerates International Expansion with Completion of Rivopharm Acquisition in Switzerland
Moroccan pharmaceutical group Laprophan finalizes its acquisition of a controlling stake in Swiss pharmaceutical firm Rivopharm, securing a strategic industrial base in Europe and expanding its global footprint.
Pharmaceutical
From Powerhouse to Pioneer: How Ireland's Life Science Sector Is Pivoting from Manufacturing to an R&D-Led Innovation Hub in 2026
An in-depth analysis of Ireland's National Life Science Innovation Strategy in 2026. We examine the structural challenges of this transition-including specialised R&D infrastructure, the acute talent shortage in cell and gene therapies (CGT), and how digital compliance tools like Priya LifePDF streamline the transition.